Insights
-
23 September 2020
Q&A with INmune’s Dr RJ Tesi: is TNF the key to treating the Covid-19 cytokine storm?
There is an urgent need to find therapies that treat the cytokine storm that is responsible for Covid-19’s high death rate. A cytokine called TNF could be the answer. INmune...
-
21 September 2020
Repurposing a COPD drug for Covid-19 with Verona Pharma
Originally developed for COPD, Verona’s ensifentrine could be a new treatment option for hospitalised Covid-19 patients. Why could this dual bronchodilator and anti-inflammatory drug be safe and effective in Covid-19...
-
2 September 2020
Next-gen Covid-19 vaccines: Elicio and its lymph node targeting approach
One next-generation Covid-19 vaccine that is about to enter clinical studies is Elicio’s ELI-005. This lymph node-targeting vaccine is composed of an adjuvant developed using the company’s Amphiphile technology and...
-
1 September 2020
Hiring from home: pharma recruitment in the age of Covid-19
UK healthcare recruitment company Carrot Pharma has been advising pharma firms on how to use remote technology to maintain hiring and onboard new staff during the coronavirus restrictions. Natalie Healey...
-
31 August 2020
Q&A with IQVIA: digital transformation in a post-Covid-19 world
The pharma industry has not been exempted from Covid-19 disruption. However, the industry has managed to pivot and adapt with help of digital strategies and technologies. IQVIA’s Tal Rosenberg discusses...
-
26 August 2020
NeuroRx’s RLF-100: the key to treating and preventing Covid-19 respiratory failure?
Dealing with respiratory failure has been a huge challenge in the Covid-19 pandemic. NeuroRx and Relief Therapeutics have teamed up to study RLF-100 on these critical Covid-19 patients. The pair...
-
12 August 2020
Selva raises $3m to develop novel antiviral against Covid-19
Selva is planning to use the $3m it has raised in a Series A round to support the early clinical development of its lead candidate SLV213 for Covid-19. SLV213 is...
-
6 August 2020
Q&A with Valneva: UK Government scales up Covid-19 manufacturing
To support Valneva’s Covid-19 vaccine VLA2001, the UK Government has agreed to make a joint investment into the company’s Scottish manufacturing facility. Valneva chief financial officer David Lawrence notes how...
-
6 August 2020
Pandemic logistics: resolving manufacturing and distribution challenges
Allocation challenges are not the only barriers to ending the Covid-19 pandemic. The need to manufacture and distribute vaccines and therapies at an unprecedented global scale also poses logistical issues....
-
5 August 2020
Discussing the UK’s Covid-19 strategy with Kate Bingham, chair of Vaccines Taskforce
To support industry and researchers in Covid-19 vaccine development and manufacturing, the UK Government set up a Vaccines Taskforce. Chair of the taskforce Kate Bingham explains its three-fold focus of...